Aprea Posts Two 50% Tumor Reductions in Phase 1 APR-1051 Trial
Two patients achieved unconfirmed partial responses in the Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051, each showing 50% tumor shrinkage and CA-125 drops to 70 and 47 U/mL. Cash fell to $14.6M at year-end 2025, but private placements raised $8.7M to fund operations into Q1 2027.
1. Financial Results and Runway
Aprea ended 2025 with cash and cash equivalents of $14.6 million, down from $22.8 million a year earlier. The company raised $3.1 million in December 2025 and $5.6 million in January 2026 through private placements, providing funding into the first quarter of 2027.
2. Proof-of-Concept Data for APR-1051
In the Phase 1 ACESOT-1051 trial, two patients with PPP2R1A-mutated endometrial cancer achieved unconfirmed partial responses at 150 mg and 220 mg doses, each showing 50% reduction in target lesions and CA-125 declines to 70 and 47 U/mL, respectively. Five additional patients across HPV+, colorectal and endometrial cohorts achieved stable disease, with APR-1051 generally well tolerated at grade 1-2 adverse events.
3. ACESOT-1051 Trial Progress and Future Milestones
Dose escalation continues at Dose Level 8 (220 mg once daily), with plans to enroll additional patients in endometrial, colorectal and HPV+ tumor cohorts. A further data update from ACESOT-1051 is expected in the second quarter of 2026 as the study evaluates optimal dose and safety profile.
4. Corporate Developments and Leadership
The company appointed Eugene Kennedy, MD, as Chief Medical Advisor to guide clinical development strategy. Private placements and leadership enhancements aim to support key milestones in the DDR-targeted oncology portfolio.